Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Pozycja w akcjach #32083
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Cena akcji
$0.21483059
Ostatnia synchronizacja: 2024-05-07
Kapitalizacja rynkowa
$11.13M
Zmiana (1 dzień)
0.34%
Zmiana (1 rok)
0.00%
Kraj
CA
Handel Antibe Therapeutics Inc. (ATE)

Kategoria

Historia stopy dywidendy dla Antibe Therapeutics Inc. (ATE)
Stopa dywidendy (TTM) dla Antibe Therapeutics Inc. (symbol akcji: ATE) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Antibe Therapeutics Inc. (ATE) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji